OncoTelic Overview

  • Founded
  • 2015

Founded
  • Status
  • Public

  • Employees
  • 16

Employees
  • Stock Symbol
  • OTLC

Stock Symbol
  • Investments
  • 2

  • Share Price
  • $0.06

  • (As of Wednesday Closing)

OncoTelic General Information

Description

Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer with a focus on rare pediatric cancers, and addressing the current global pandemic. OT-101 is its lead immuno-oncology drug candidate. OT-101 also has activity against SARS-CoV-2. Its other products under pipeline are Artemisinin, CA4P, and Oxi4503. Currently, the company generates revenues from rendering services to other third-party customers for the development of certain drug products or in connection with certain out-licensing agreements.

Contact Information

Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
PINX
Primary Office
  • 29397 Agoura Road
  • Suite 107
  • Agoura Hills, CA 91301
  • United States
+1 (650) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoTelic Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.06 $0.06 $0.05 - $0.26 $24.9M 386M 248K $0.03

OncoTelic Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 74,532 70,203 21,907 14,796
Revenue 0 0 1,741 0
EBITDA 9,538 (8,453) (7,609) (5,828)
Net Income 7,806 (9,391) (9,503) (6,638)
Total Assets 40,388 23,613 23,663 23,685
Total Debt 9,802 8,993 4,653 1,501
Public Fundamental Data provided by Morningstar, Inc. disclaimer

OncoTelic Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.

Request a free trial

OncoTelic Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Oncotelic Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing drugs for the treatme
Biotechnology
Agoura Hills, CA
16 As of 2021
00.00
000000000 00.00

000000

olore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui of
0000 000000000
San Carlos, CA
00 As of 0000
00000
000000000 00000

000000

rcitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehen
0000 000000000
Palo Alto, CA
00 As of 0000
00000
0000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoTelic Competitors (4)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Apexigen Formerly VC-backed San Carlos, CA 00 00000 000000000 00000
000000-000 0000000 Venture Capital-Backed Palo Alto, CA 00 00000 0000000000 00000
00000 00000000 Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
000000 00000000000 Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
To view OncoTelic’s complete competitors history, request access »

OncoTelic Executive Team (15)

Name Title Board Seat Contact Info
Amit Shah Chief Financial Officer
Chulho Park Ph.D Chief Technology Officer
Saranjit Saund Chief Business Officer & General Manager of AI Division
Seymour Fein MD Chief Regulatory Officer
Fatih Uckun Ph.D Chief Medical Officer
You’re viewing 5 of 15 executive team members. Get the full list »

OncoTelic Board Members (8)

Name Representing Role Since
Anthony Maida Ph.D Self Chief Clinical Officer - Translational Medicine 000 0000
Frederick Driscoll Self Chief Executive Officer & Board Member 000 0000
You’re viewing 2 of 8 board members. Get the full list »

OncoTelic Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoTelic Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore OncoTelic‘s full profile, request access.

Request a free trial

OncoTelic Investments & Acquisitions (2)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000000 31-Mar-2022 00000 0000 Drug Discovery 00000 000
Mateon Therapeutics 25-Apr-2019 Merger/Acquisition Drug Discovery 00000 000
To view OncoTelic’s complete investments and acquisitions history, request access »